Botanix Pharmaceuticals' (ASX:BOT) stock slump is backed by no "good" company-specific reason aside from broader macroeconomic factors, said Euroz Hartleys in a Thursday note.
The stock has seen continuous sessions of losses since it reported a wider fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
The research firm believes the company's half-year results were unsurprising, and the extent of the stock's decline remains "puzzling."
The company will see a negligible financial impact from the newly imposed 25% tariff on Canadian exports, the note added.
The research firm maintained its buy rating and price target of AU$0.55 on Botanix Pharmaceuticals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。